Helping you and your doctor chart a course—that includes treatment with the flexibility of once-yearly VANTAS

Like the thousands of men who have advanced prostate cancer, you probably have a lot of questions about your health, your treatment, and many other issues.

Now that you and your doctor have chosen once-yearly VANTAS to help in the treatment of your prostate cancer, we can help you find answers to those questions. This Web site was created for you.

With the VANTAS implant, you receive effective therapy for 12 months with just one treatment, instead of a series of injections. The convenience of a once-yearly implant gives you more freedom to spend your time your way.

This Web site is a comprehensive resource that's always available to quickly answer your questions and support your treatment program. Here you'll find:

More information about VANTAS

Frequently asked questions (FAQs) about VANTAS

Answers to questions about prostate health

Caregiver Information

We’ve also included helpful links to help you find national prostate health organizations and support groups, and even a glossary of medical terms. You’ll also be able to download handy, informative materials to answer any questions you may have about VANTAS between your doctor visits.

Important Safety Information

VANTAS is contraindicated in women, pediatric patients and patients with hypersensitivity to GnRH, GnRH agonist analogs, or any of the other components of VANTAS.

VANTAS, like other LHRH agonists, causes a transient increase in serum concentrations of testosterone during the first week of treatment. Patients may experience worsening of symptoms or onset of new symptoms, including bone pain, neuropathy, hematuria, or ureteral or bladder outlet obstruction, cases of ureteral obstruction and spinal cord compression. Patients with metastatic vertebral lesions and/or with urinary tract obstruction should be closely observed during the first few weeks of therapy.

Implant insertion and removal is a surgical procedure and should use aseptic technique. Careful adherence to the recommended insertion and removal procedures is recommended. In all clinical trials combined, an implant was not recovered in 8 patients, 2 of these 8 patients had serum testosterone levels above castrate level and the implant was not visualized with ultrasound. In all of the 8 patients, the implant was not palpable.

Response to VANTAS should be monitored measuring serum concentrations of testosterone and PSA periodically.

In clinical trials, the most common adverse reactions were hot flashes, fatigue, and implant site reaction. During post-marketing surveillance, rare cases of pituitary apoplexy have been reported after the administration of GnRH agonists.

Helping you and your doctor chart a course—that includes treatment with the flexibility of once-yearly VANTAS

Click here for a larger view

Important Safety Information